Prosecution Insights
Prosecution Insights
7 pending office actions • 7 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (29%) |
| Multi-statute (no §101) | 5 (71%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| UNDERDAHL, THANE E | 1 | 58.9% | +50.6% |
| LE, KHOA TAN | 1 | 78.6% | +37.5% |
| KINSEY WHITE, NICOLE ERIN | 1 | 58.0% | +16.2% |
| SU-TOBON, QIWEN NMN | 1 | 75.0% | +100.0% |
| BLUMEL, BENJAMIN P | 1 | 70.7% | +30.6% |
| SKELDING, ZACHARY S | 1 | 59.7% | +41.3% |
| XU, QING | 1 | 50.7% | +54.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17449723 | COMPOUNDS AND METHODS FOR TREATING LIVER DISEASES | XU, QING | 36d overdue |
| 18405956 | COMPOUND AND METHOD FOR AN ALLELE-SPECIFIC EDITING OF THE ELANE GENE | UNDERDAHL, THANE E | — |
| 18453993 | METHOD AND COMPOSITION FOR A TARGETED GENE KNOCKOUT | SU-TOBON, QIWEN NMN | — |
| 18164313 | Peptides and Combinations of Peptides for Use in Immunotherapy Against an Infection by Sars-COV-2 (COVID-19) | BLUMEL, BENJAMIN P | — |
| 18052037 | PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEMATOLOGIC NEOPLASMS AND OTHER CANCERS | SKELDING, ZACHARY S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17449723 | COMPOUNDS AND METHODS FOR TREATING LIVER DISEASES | XU, QING | 36d overdue |
| 18525208 | SURGICAL DEVICE FOR CLAMPING IN TISSUE | LE, KHOA TAN | 72d |
| 18405956 | COMPOUND AND METHOD FOR AN ALLELE-SPECIFIC EDITING OF THE ELANE GENE | UNDERDAHL, THANE E | — |
| 18500468 | METHOD FOR DIAGNOSING A PREDISPOSITION OF A LIVING BEING TO DEVELOP THROMBOCYTOPENIA | KINSEY WHITE, NICOLE ERIN | — |
| 18453993 | METHOD AND COMPOSITION FOR A TARGETED GENE KNOCKOUT | SU-TOBON, QIWEN NMN | — |
| 18164313 | Peptides and Combinations of Peptides for Use in Immunotherapy Against an Infection by Sars-COV-2 (COVID-19) | BLUMEL, BENJAMIN P | — |
| 18052037 | PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEMATOLOGIC NEOPLASMS AND OTHER CANCERS | SKELDING, ZACHARY S | — |
| Art Unit | Apps |
|---|---|
| 1699 | 1 |
| 3771 | 1 |
| 1672 | 1 |
| 1636 | 1 |
| 1671 | 1 |
| 1644 | 1 |
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18405956 | COMPOUND AND METHOD FOR AN ALLELE-SPECIFIC EDITING OF THE ELANE GENE | UNDERDAHL, THANE E | 1699 | §102§103§112 | Final Rejection | — | Pending | Jan 05, 2024 |
| 18525208 | SURGICAL DEVICE FOR CLAMPING IN TISSUE | LE, KHOA TAN | 3771 | §103 | Final Rejection | 72d | Pending | Nov 30, 2023 |
| 18500468 | METHOD FOR DIAGNOSING A PREDISPOSITION OF A LIVING BEING TO DEVELOP THROMBOCYTOPENIA | KINSEY WHITE, NICOLE ERIN | 1672 | §103 | Non-Final OA | — | Pending | Nov 02, 2023 |
| 18453993 | METHOD AND COMPOSITION FOR A TARGETED GENE KNOCKOUT | SU-TOBON, QIWEN NMN | 1636 | §103§112Other | Non-Final OA | — | Pending | Aug 22, 2023 |
| 18164313 | Peptides and Combinations of Peptides for Use in Immunotherapy Against an Infection by Sars-COV-2 (COVID-19) | BLUMEL, BENJAMIN P | 1671 | §102§112 | Non-Final OA | — | Pending | Feb 03, 2023 |
| 18052037 | PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEMATOLOGIC NEOPLASMS AND OTHER CANCERS | SKELDING, ZACHARY S | 1644 | §102§103§112 | Non-Final OA | — | Pending | Nov 02, 2022 |
| 17449723 | COMPOUNDS AND METHODS FOR TREATING LIVER DISEASES | XU, QING | 1656 | §103§112 | Non-Final OA | 36d overdue | Pending | Oct 01, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial